Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts.
about
Current perspectives on pancreatic serous cystic neoplasms: Diagnosis, management and beyondClinical approach to incidental pancreatic cystsEndoscopic ultrasound-guided fine-needle aspiration for the diagnosis of pancreatic cysts by combined cytopathology and cystic content analysisCytology Specimen Management, Triage and Standardized Reporting of Fine Needle Aspiration Biopsies of the PancreasUtility of molecular tests in cytopathologyMolecular pathology of intraductal papillary mucinous neoplasms of the pancreas.Endosonography in the diagnosis and management of pancreatic cystsManagement of serous cystic neoplasms of the pancreas.Does EUS-FNA molecular analysis carry additional value when compared to cytology in the diagnosis of pancreatic cystic neoplasm? A systematic reviewKRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound.Advanced endoscopic ultrasound management techniques for preneoplastic pancreatic cystic lesionsDigital PCR Improves Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy Specimens.The value of KRAS mutation testing with CEA for the diagnosis of pancreatic mucinous cysts.Papanicolaou Society of Cytopathology new guidelines have a greater ability of risk stratification for pancreatic endoscopic ultrasound-guided fine-needle aspiration specimens.Systematic Review of Pancreatic Cyst Fluid Biomarkers: The Path Forward.Role of emerging molecular markers in pancreatic cyst fluid.Imaging modalities for characterising focal pancreatic lesions.Team work and cytopathology molecular diagnosis of solid pancreatic lesions.Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen.Low interobserver agreement in cytology grading of mucinous pancreatic neoplasms.Do molecular tests really differentiate malignant IPMNS from benign?Diagnosis and Management of Pancreatic Cystic Neoplasms.Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression.Confocal endomicroscopy and cyst fluid molecular analysis: Comprehensive evaluation of pancreatic cysts.Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma.Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas.Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS.
P2860
Q26750210-5EC19716-1246-4521-AB6C-DA59125EB147Q26774489-D660167D-CC49-4413-817C-E0A55127A9B5Q26778647-93D51BD4-F2D9-401B-86B1-4B36283F9AFCQ26799060-EC7CD04C-620E-4356-B6FC-41666EAB8A97Q33555932-52E15EF1-C73A-4BBC-A8CD-0C14CDF7D633Q34008627-D06619CE-2979-4E9C-ADFA-8CC0A14EC38EQ35179268-D865BF9E-CA4E-4BF3-87CB-01BE4CC7C1A3Q35198797-91575B8E-3BAD-4E68-9616-363BC7677927Q35468979-FD744496-B5EC-4603-8EE9-5F4DC67F3E07Q35498705-C3164EB5-9A4F-45F1-84CA-47C652061BF7Q36116543-7044B19B-2F9C-442A-AB82-DDFA3B5E02D3Q36261430-791B0DFB-CD8B-484F-9378-1E9D8282D44AQ36798760-A4555B4C-624F-4AAB-867B-2B288CF86A53Q37702678-80DA8425-B4E3-4756-BC70-DDA302F9BAE0Q38525151-9B0B4501-B257-46BD-AADC-AF6070BBF26CQ38661563-A777D8CC-6628-4562-AF4D-B9184442E07AQ38834240-F0C8E7B0-1882-495B-9123-7F02F1B7CB14Q39132122-15733ABE-66B2-4BCE-A8F9-5410791AC267Q40234593-6A49F3EF-DC7A-416E-813D-703754C1D709Q41833076-A2A88589-FF8E-42DD-AAF8-42269C737883Q42350987-747DBCAD-7986-415B-88F3-FAFEFC8B56EFQ47880483-5605495C-8142-4CE5-BDDD-F52610087C66Q48155929-17929577-EEA1-42C7-A38E-C59B875332FBQ48344381-F0F63A2E-5CA8-4168-85C0-C7C407EA6205Q49629569-C5E84C3B-08E1-4A58-A23A-3D0115E7431BQ50101175-5F40EA7D-3E13-4707-8518-01FF4F03C931Q50923886-49C8F3E9-D21B-46E8-A20A-B8F9721D5EC0Q53625072-85B91861-58A5-455F-A436-6E726EEB231DQ55104265-CF072116-A4D3-45D1-8852-9C34779C64B9Q55154078-95E8BDB5-D47C-4978-908E-103D098C5D14
P2860
Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Integration of KRAS testing in ...... ience of 618 pancreatic cysts.
@en
Integration of KRAS testing in ...... ience of 618 pancreatic cysts.
@nl
type
label
Integration of KRAS testing in ...... ience of 618 pancreatic cysts.
@en
Integration of KRAS testing in ...... ience of 618 pancreatic cysts.
@nl
prefLabel
Integration of KRAS testing in ...... ience of 618 pancreatic cysts.
@en
Integration of KRAS testing in ...... ience of 618 pancreatic cysts.
@nl
P2093
P2860
P1433
P1476
Integration of KRAS testing in ...... ience of 618 pancreatic cysts.
@en
P2093
Aatur D Singhi
Adam Slivka
Alyssa M Krasinskas
Amer H Zureikat
Asif Khalid
Geeta S Mantha
Herbert J Zeh
Jennifer S Chennat
Karen E Schoedel
Kenneth E Fasanella
P2860
P2888
P304
P356
10.1038/MODPATHOL.2013.91
P577
2013-06-07T00:00:00Z